Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 16;28(15):3277–3286. doi: 10.1158/1078-0432.CCR-21-0985

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. Treatment and outcomes of 3-year survivors in nivolumab group. Swimmer plot represent treatment-free period, discontinuations, BOR, and subsequent therapy of 3-year survivors (n = 31) in the nivolumab group. CDDP, cisplatin; CR, complete response; DOX, docetaxel; 5-FU, 5-Fluorouracil; L-OHP, oxaliplatin; NE, not evaluable; Nivo, Nivolumab; PTX, paclitaxel. — Treatment and outcomes of 3-year survivors in nivolumab group. Swimmer plot represents treatment-free period, discontinuations, BOR, and subsequent therapy of 3-year survivors (n = 31) in the nivolumab group. CDDP, cisplatin; CR, complete response; DOX, docetaxel; 5-FU, 5-fluorouracil; L-OHP, oxaliplatin; NE, not evaluable; Nivo, nivolumab; PTX, paclitaxel.